Current trials: Diffuse Large B-Cell Lymphoma (DLBCL)57

The following clinical trials are currently offered in Germany in this group. More about Diffuse Large B-Cell Lymphoma (DLBCL)

57 matching trials

CHARLYActive, not recruiting

Cyclophosphamide to Reduce Complications Following Haploidentical Stem Cell Transplantation

If non-Hodgkin lymphoma (NHL) cannot be controlled with standard therapy (refractory), a stem cell transplant from a compatible donor may be recommended. In a so-called haploidentical stem cell transplant, the immunological similarity between the donor and the recipient is lower, and rejection reactions may occur as a complication of the transplant. This risk could potentially be reduced by administering a high dose of the drug cyclophosphamide. The aim of the study is to investigate whether high-dose cyclophosphamide administered after a haploidentical stem cell transplant can prolong disease-free survival and reduce the risk of rejection reactions. Women and men aged 18–65 with relapsed or refractory NHL who are receiving a haploidentical allogeneic stem cell transplant are eligible to participate in this study.

18–65 years · Relapsed / refractory · Phase II

B-NHL 2013Recruiting

A study on the treatment protocol of the NHL-BFM and NOPHO Studien GruppenT for mature B-cell non-Hodgkin lymphoma and Burkitt leukemia in children and adolescents (B-NHL 2013)

Lymphomas and leukemias are malignant diseases of the blood cells that vary greatly in their presentation and prognosis. The aggressive subtypes spread rapidly and usually require prompt treatment, most often a combination of chemotherapy and an antibody. The goal of the B-NHL 2013 study is to investigate the efficacy of the antibody rituximab in addition to standard chemotherapy for aggressive mature B-cell non-Hodgkin lymphomas (B-NHL) and Burkitt leukemia (B-AL), and to compare it with the treatment currently in use. Patients who have been newly diagnosed with these diseases and are under 18 years of age are eligible to participate in the study.

0–18 years · First line · Phase III

DALY 2-EURecruiting

DALY-2

The DALY-2 study aims to investigate whether, in patients with a relapse of an aggressive form of lymphoma (known as DLBCL), the body’s own modified immune cells (known as CAR-T cells) are more effective than chemotherapy.

18–70 years · Relapsed / refractory · Phase II

GOAL IIActive, not recruiting

GOAL II

The GOAL-II trial is investigating the efficacy of adding a new antibody to existing standard therapy in patients with relapsed aggressive lymphoma.

18–64 years · Relapsed / refractory · Phase II

frontMIND / MOR208C310Active, not recruiting

FRONTMIND

The FRONTMIND study is investigating whether adding an antibody (tafasitamab) and an immunomodulatory agent (lenalidomide) to the current standard of care improves treatment outcomes for aggressive lymphoma (B-NHL).

18–80 years · Phase III

OptiMATeRecruiting

Is a reduced-intensity version of the current standard treatment sufficient for central nervous system lymphoma?

Lymphomas are malignant diseases of white blood cells that typically manifest in the blood and lymph nodes, but can also primarily affect the central nervous system (CNS) (PCNSL). This requires intensive treatment based on established treatment protocols. The goal of the OptiMATe study is to investigate whether a reduced-intensity therapy is just as effective as standard treatment according to the MATRix protocol and may cause fewer side effects. Women and men between the ages of 18 and 70 with PCNSL are eligible to participate in this study. The lymphoma must not be located outside the CNS.

18–70 years · First line · Phase III

PRIMA-CNSRecruiting

Study of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Comparison of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation with Conventional Chemotherapy Using R-MP (Rituximab + Methotrexate + Procarbazine)

The PRIMA-CNS study is designed for older patients with malignant primary central nervous system lymphoma (PCNSL), a rare form of cancer affecting the brain and spinal cord. The goal of the study is to compare two treatment approaches to determine which therapy is better tolerated and achieves better long-term treatment outcomes. Patients aged 65 and older with newly diagnosed PCNSL who are physically fit enough for more intensive therapy are eligible to participate in the study.

65 years and older · First line · Phase III

MK-4280-003Active, not recruiting

Evaluation of the Safety and Efficacy of Combination Therapy with Favezelimab and Pembrolizumab and the Respective Monotherapies in Hodgkin's and Non-Hodgkin's Lymphomas

Lymphomas are a group of blood cancers that affect the lymphatic system. They are classified into several subgroups based on the types of cells involved and the aggressiveness of the disease. Various treatments are used, including immunotherapy drugs that help the immune system fight cancer cells. This study (MK-4280-003) is intended for patients with classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), or indolent non-Hodgkin lymphoma (iNHL). The goal is to investigate the safety, optimal dosage, and efficacy of favezelimab in combination with pembrolizumab, both of which are immunomodulatory drugs. Adult patients who have one of these conditions and measurable tumors are eligible to participate.

18 years and older · Relapsed / refractory · Phase I/II

BGB-16673-101Recruiting

New treatment approach (drug: BGB-16673) as an adjunct to standard therapy with BTK inhibitors for various B-cell lymphomas

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system for which, in certain cases, therapy with a Bruton’s tyrosine kinase inhibitor (BTK inhibitor) is a treatment option. A new mechanism of action (drug: BGB-16673) does not inhibit BTK but instead targets its destruction. The goal of the CaDAnCe-101 study is to investigate the optimal dosage, safety, and efficacy of the drug BGB-16673. Patients aged 18 and older with a variety of different NHLs are eligible to participate in the study. There must be no involvement of the central nervous system (CNS).

18 years and older · Relapsed / refractory · Phase I/II

ELM-2Recruiting

A new antibody (Odronextamab) for the treatment of B-cell non-Hodgkin lymphomas in patients who have already received prior treatment

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system that can occur in various subtypes. Standard treatment often consists of immunochemotherapy; however, the disease may remain active (refractory) or become active again (recurrence). Odronextamab is a new antibody that targets cancer cells while simultaneously stimulating the immune system (bispecific). It is already approved for treatment in certain situations. The ELM-2 study is investigating the efficacy and safety of this new antibody (odronextamab). The study is open to women and men aged 18 and older who have follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or another subtype of B-cell NHL, and whose disease is either refractory or has relapsed.

18 years and older · Relapsed / refractory · Phase II